RxDoctor Payments Data

Sarah Bradley, MD

Urogynecology and Reconstructive Pelvic Surgery · Cary, NCNPI 1861789554

Payments from drug & device makers

What this record shows

This record is dominated by education: $8,632 of the $10,979 with a category attached, or 78.6%. Intuitive Surgical accounts for 82.3% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2024 at $6,287 and has fallen 50.6% since, to $3,108 in 2025.

$10,979in general payments, 2019–2025

Across 89 payments — averaging $123.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$9K
  • Coloplast$427
  • Axonics, Inc.$238
  • AbbVie$217
  • Astellas Pharma US Inc$213
  • Boston Scientific$202
  • plus $649 from 13 others

What the payments were for

  • Travel & lodging$4814%
  • Food & beverage$1,86617%
  • Education$8,63279%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,979 in reported general payments places this provider in the 75th percentile of 35 urogynecology and reconstructive pelvic surgery providers in North Carolina.

See all urogynecology and reconstructive pelvic surgery providers in North Carolina

Medicare billing

Part B allowed, 2024
$135,293
Medicare patients
261
Services billed
2,826

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron235$186,927
MyrbetriqMirabegron134$98,612
PremarinEstrogens, Conjugated28$12,392
Estradiol76$5,978
Solifenacin Succinate37$1,342
Clobetasol Propionate29$750
Methenamine Hippurate11$713
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst57$640
Cephalexin33$312
Oxybutynin Chloride ErOxybutynin Chloride18$293
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip11$207
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen40$107
Fluconazole13$104
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim28$60
Triamcinolone Acetonide12$44

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$120$186,927235 claims
Astellas Pharma US IncMyrbetriq$213$98,612134 claims
PfizerPremarin$111$12,39228 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 35 urogynecology and reconstructive pelvic surgery providers in North Carolina.

Other urogynecology and reconstructive pelvic surgery in Cary

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →